JNJ ▲ +0.5% - Johnson & Johnson $JNJ - Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy 02-OCT-2026 06:00 AM ET